1
|
Liu T, Brown TC, Juhlin CC, Andreasson A, Wang N, Bäckdahl M, Healy JM, Prasad ML, Korah R, Carling T, Xu D, Larsson C. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. Endocr Relat Cancer 2014; 21:427-34. [PMID: 24803525 PMCID: PMC4045219 DOI: 10.1530/erc-14-0016] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The telomerase reverse transcriptase gene (TERT) encodes the reverse transcriptase component of the telomerase complex, which is essential for telomere stabilization and cell immortalization. Recent studies have demonstrated a transcriptional activation role for the TERT promoter mutations C228T and C250T in many human cancers, as well as a role in aggressive disease with potential clinical applications. Although telomerase activation is known in adrenal tumors, the underlying mechanisms are not established. We assessed C228T and C250T TERT mutations by direct Sanger sequencing in tumors of the adrenal gland, and further evaluated potential associations with clinical parameters and telomerase activation. A total of 199 tumors were evaluated, including 34 adrenocortical carcinomas (ACC), 47 adrenocortical adenomas (ACA), 105 pheochromocytomas (PCC; ten malignant and 95 benign), and 13 abdominal paragangliomas (PGL; nine malignant and four benign). TERT expression levels were determined by quantitative RT-PCR. The C228T mutation was detected in 4/34 ACCs (12%), but not in any ACA (P=0.028). C228T was also observed in one benign PCC and in one metastatic PGL. The C250T mutation was not observed in any case. In the ACC and PGL groups, TERT mutation-positive cases exhibited TERT expression, indicating telomerase activation; however, since expression was also revealed in TERT WT cases, this could denote additional mechanisms of TERT activation. To conclude, the TERT promoter mutation C228T is a recurrent event associated with TERT expression in ACCs, but rarely occurs in PGL and PCC. The involvement of the TERT gene in ACC represents a novel mutated gene in this entity.
Collapse
Affiliation(s)
| | - Taylor C Brown
- Yale Endocrine Neoplasia Laboratory, Yale School of Medicine333 Cedar Street, FMB130A, PO Box 208062, New Haven, Connecticut, 06520USA
- Department of Surgery, Yale School of MedicineNew Haven, ConnecticutUSA
| | - C Christofer Juhlin
- Yale Endocrine Neoplasia Laboratory, Yale School of Medicine333 Cedar Street, FMB130A, PO Box 208062, New Haven, Connecticut, 06520USA
- Department of Surgery, Yale School of MedicineNew Haven, ConnecticutUSA
- Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital CCKStockholm, SE-171 76Sweden
- Correspondence should be addressed to C C Juhlin,
| | - Adam Andreasson
- Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital CCKStockholm, SE-171 76Sweden
| | - Na Wang
- Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital CCKStockholm, SE-171 76Sweden
| | - Martin Bäckdahl
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University HospitalStockholm, SE-171 76Sweden
| | - James M Healy
- Yale Endocrine Neoplasia Laboratory, Yale School of Medicine333 Cedar Street, FMB130A, PO Box 208062, New Haven, Connecticut, 06520USA
- Department of Surgery, Yale School of MedicineNew Haven, ConnecticutUSA
| | - Manju L Prasad
- Department of Pathology, Yale School of MedicineNew Haven, ConnecticutUSA
| | - Reju Korah
- Yale Endocrine Neoplasia Laboratory, Yale School of Medicine333 Cedar Street, FMB130A, PO Box 208062, New Haven, Connecticut, 06520USA
- Department of Surgery, Yale School of MedicineNew Haven, ConnecticutUSA
| | - Tobias Carling
- Yale Endocrine Neoplasia Laboratory, Yale School of Medicine333 Cedar Street, FMB130A, PO Box 208062, New Haven, Connecticut, 06520USA
- Department of Surgery, Yale School of MedicineNew Haven, ConnecticutUSA
| | | | - Catharina Larsson
- Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital CCKStockholm, SE-171 76Sweden
| |
Collapse
|
2
|
Yang D, Qi Y, Chen Q, Wang Z, Jin X, Gao J, Fu J, Xiao X, Zhou Z. The over-expression of p53 H179Y residue mutation causes the increase of cyclin A1 and Cdk4 expression in HELF cells. Mol Cell Biochem 2007; 304:219-26. [PMID: 17530187 DOI: 10.1007/s11010-007-9503-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2007] [Accepted: 04/27/2007] [Indexed: 01/10/2023]
Abstract
Down-regulation of p53 expression has been found in a broad range of human cancers and cell proliferation disorders, indicating that p53 plays a key role in cell cycle regulation and tumor suppression. In our current study, we transfected human embryonic lung fibroblast (HELF) cells with pcDNA3-wild-type p53 (pcDNA3-wtp53) plasmid, or pcDNA3-H179Y-mutated p53 (pcDNA3-mtp53) plasmid that mimics the mutation found in some human lung tumors, and further studied the role of p53 in the regulation of cell proliferation. Over expression of wild-type p53 caused cell cycle arrest at G1 phase with reduced cell size, decreased expression of cyclin D3, cyclin E, Cdk2 and Cdk4, and increased expression of p21. In contrast, over expression of H179Y-mutant p53 promoted G1 to S phase transition with enlarged cell size and increased cyclin A1 and Cdk4 expression in HELF cells. These results indicate that mutation at the p53 H179Y residue up-regulates cyclin A1 and Cdk4 expression, and promotes HELF cell proliferation.
Collapse
Affiliation(s)
- Di Yang
- Department of Pharmacology and Toxicology, College of Veterinary Medicine, China Agricultural University, Beijing 100094, P.R. China
| | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Liu H, Wang Y, Zhou Q, Gui SY, Li X. The point mutation of p53 gene exon7 in hepatocellular carcinoma from Anhui Province, a non HCC prevalent area in China. World J Gastroenterol 2002; 8:480-2. [PMID: 12046074 PMCID: PMC4656425 DOI: 10.3748/wjg.v8.i3.480] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: In hepatocellular carcinoma (HCC) prevalent areas of China, the point mutation of p53 exon7 is highly correlated with Hepatitis B virus (HBV) infection and aflatoxin B intake. While in non-HCC-prevalent areas of China, these factors are not so important in the etiology of HCC. Therefore, the point mutation of p53 exon7 may also be different than that in HCC-prevalent areas of China. The aim of this study is to investigate the status and carcinogenic role of the point mutation of p53 gene exon7 in hepatocellular carcinoma from Anhui Province, a non-HCC-prevalent area in China.
METHODS: PCR, PCR-SSCP and PCR-RFLP were applied to analyze the homozygous deletion and point mutation of p53 exon7 in HCC samples from Anhui, which were confirmed by DNA sequencing and Genbank comparison.
RESULTS: In the 38 samples of hepatocellular carcinoma, no homozygous deletion of p53 exon7 was detected and point mutations of p53 exon7 were found in 4 cases, which were found to be heterozygous mutation of codon 249 with a mutation rate of 10.53% (4/38). The third base mutation (GiúT) of p53 codon 249 was found by DNA sequencing and Genbank comparison.
CONCLUSION: The incidence of point mutation of p53 codon 249 is lower in hepatocellular carcinoma and the heterozygous mutation of p53 exon7 found in these patients only indicate that they have genetic susceptibility to HCC. p53 codon 249 is a hotspot of p53 exon7 point mutation, suggesting that the point mutation of p53 exon 7 may not play a major role in the carcinogenesis of HCC in Anhui Province, a non-HCC-prevalent area in China.
Collapse
Affiliation(s)
- Hu Liu
- Laboratory of Molecular Biology and Department of biochemistry, Anhui Medical University, Hefei 230032, Anhui Province, China
| | | | | | | | | |
Collapse
|